The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The novel ICAHT grading system to predict toxicity following CAR T-cell therapy
Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, introduces the novel immune effector cell–associated hematotoxicity (ICAHT) grading system for hematological toxicities following CAR T-cell therapy. In a multicenter retrospective cohort of patients with large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), and multiple myeloma (MM), this system accurately discriminated between the severity of infection and predicted outcomes of CAR T-cell therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS/CELGENE
Honoraria: BMS/CELGENE, Novartis
Travel Support: Kite/Gilead, Pierre-Fabre
Research Funding: Kite/Gilead
